Navigation Links
ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
Date:3/21/2008

PRINCETON, N.J., March 21 /PRNewswire-USNewswire/ -- In a short article published today by the Washington Legal Foundation, US international trade and business lawyer Lawrence Kogan and Russian Government lawyer Yelena Bakulina highlight the common bases in Russian and US history that have triggered new thinking in Russia about how to use privately owned patent rights and cooperative government-university-industry technology transfer arrangements to secure successful market commercialization and peaceful adaptation of publicly-owned bio-warfare technologies.

The article arose from Kogan's June 28, 2007 presentation at a symposium convened by the Vyatka State University, Kirov, Russia, as part of a longstanding joint Russian-US cooperative nonproliferation program overseen by the International Science and Technology Center (ISTC), Moscow, Russia.

According to Bakulina and Kogan, "The [US] federal government['s]...transference of innovation from energy, space, and defense to that of the private sector, and...the American experience in innovation and intellectual property may be advantageous to use in Russia..."

Furthermore as the authors note, "The Kirov Region certainly has the potential to develop effective innovation systems supported by the investment and protection of privately owned intellectual property in the sphere of modern high tech technology. If properly managed...this could create jobs, know-how and other economic and social benefits in the Kirov Region."

"Such an approach," adds Kogan, "would allow Russian biotechnology markets to leapfrog those of the European Union to capture a greater share of the global marketplace for biomedical and bioenvironmental products and processes. Unfortunately, the current EU innovation model is fixated on governmental market control via regulation rather than on market facilitation via economic incentives that ease the burdens and costs of doing business," emphasizes Kogan. "The EU Commission is more obsessed with dictating the rules of the game to ensure 'parity-over-progress' than with providing hi tech European businesses operating in the biotech sectors with the necessary property rights-based enabling environment and economic freedom to grow and prosper. "Consequently," Kogan notes, "EU biotech and pharma companies have increasingly relocated operations to the US."

The Institute for Trade, Standards and Sustainable Development (ITSSD) is a non-partisan non-profit international legal research and educational organization that examines international law relating to trade, industry and positive sustainable development around the world. This and related ITSSD articles are accessible online at: http://www.itssd.org/Publications/03-21-08balukina.pdf; http://www.itssd.org and http://itssdinternationaliprights.blogspot.com.

CONTACT: ITSSD, +1-609-951-2222, info@itssd.org


'/>"/>
SOURCE Institute for Trade, Standards, and SustainableDevelopment
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
2. Amarin Secures Global Intellectual Property Rights for Lipid Programs
3. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. ProMetic provides business update - Over $35 million worth of business secured in January
6. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
7. Taligen Therapeutics Secures Series B Financing
8. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
9. Dendreon Secures $130 Million Committed Equity Financing Facility
10. Secure Symbology: Making New Jersey Proud While Saving Lives
11. Apollo Endosurgery, Inc. Secures $11.5 Million in Series A Financing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):